DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing ...
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am ...
The notification letter has no immediate effect on the listing of the Company’s class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD”.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance ...
The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635 (c) (4).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which ...
MicroTransponder®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim® Paired VNS™ System for chronic stroke recovery, has joined the American Heart ...
This Breakthrough Therapy designation recognizes the potential for ianalumab to substantially improve the standard of care for people with Sjögren’s disease, who currently don't have effective ...
About GlohCo GlohCo is a healthtech intelligence platform focused on building software and data-driven tools for use across digital health and care delivery environments.
In 2025, Baylor Genetics was named an official genetic testing partner of the Child Neurology Society.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback